Practical Tools for Screening Female Athletes

The Screening Divide

Elite athletes operate within sophisticated support systems providing regular, comprehensive health monitoring. Research from UK Athletics demonstrates how integrated performance health management models deliver systematic screening across cardiovascular, metabolic, nutritional, and psychological domains⁽¹⁾. These athletes undergo periodic health evaluations every two to three years, with annual focused assessments between cycles to detect emerging issues. The infrastructure typically includes full-time sports medicine physicians, physiotherapists, nutritionists, and sport psychologists.

Semi-elite and recreational athletes face a starkly different reality (see Table 1). Most compete with minimal systematic health evaluation beyond basic preparticipation screenings. Even common conditions affecting performance remain largely undetected in athletic populations. For example, a study examining 300 exercising women at a national fitness festival found that 12% had anemia, 43% reported a history of iron deficiency, and 43% experienced heavy menstrual bleeding; conditions that directly impact athletic performance⁽²⁾. The absence of regular, comprehensive monitoring means such performance-limiting conditions persist unrecognized, silently compromising training adaptation and competitive capacity.

This screening disparity creates tangible consequences. For example, ~30% of exercising females have a history of anemia, and ~50% have used iron supplements, yet only a minority (~22%) had sought medical advice⁽³⁾. Similarly, unidentified cardiovascular abnormalities, psychological distress, and metabolic dysfunction silently erode performance capacity while increasing injury risk. The gap between elite and semi-elite screening represents more than a resource issue; it reflects broader disparities in access to comprehensive health monitoring.

Table 1: Elite vs Semi-elite Screening Comparison

Beyond One-dimensional Screening

Even when screening occurs systematically, critical blind spots persist. Research from Johns Hopkins Medical Institutions reveals that routine athlete screenings frequently focus on isolated physical parameters while neglecting interconnected health domains⁽⁴⁾. For example, blood work may assess hemoglobin but overlook ferritin, allowing iron depletion to progress undetected. Cardiovascular evaluation may identify structural abnormalities but miss functional limitations. Physical screening occurs in isolation from psychological well-being assessment.

This pattern extends particularly to mental health. For example, 20% of Collegiate athletes experience significant psychological problems annually⁽⁵⁾. However, fewer than half of collegiate sports medicine departments administer screening instruments for mental health concerns. An athlete might complete comprehensive musculoskeletal and cardiovascular screening yet receive no formal evaluation of psychological well-being.
The consequences extend beyond subjective well-being. There is an elevated injury risk and diminished performance among athletes experiencing depression symptoms or eating disorders. Researchers from the University of Melbourne emphasize that the transition into elite-level sport exposes young athletes to risk factors, including increased performance expectations and public scrutiny pressures⁽⁶⁾. Without systematic psychological screening, these stressors accumulate silently until they manifest as performance decrements, injuries, or burnout.

A multidimensional screening framework acknowledges that optimal performance emerges from the synergistic interaction of multiple health domains. Integrating physical, psychological, nutritional, and recovery assessments into unified protocols will improve athletic performance. This approach recognizes that iron deficiency affects both oxygen-carrying capacity and cognitive function; that sleep deprivation affects both injury risk and decision-making; and that psychological distress affects both immune function and muscular recovery.

"The gap between elite and semi-elite screening represents more than a resource issue..."

Implementing Multidimensional Screening

Translating research-based screening protocols into practical tools for semi-elite settings requires careful consideration of feasibility, cost-effectiveness, and time efficiency. The challenge lies in adapting comprehensive assessment frameworks to resource-limited environments while preserving their ability to detect performance-limiting conditions. There are eight domains that require screening to create meaningful interventions. In this article, we will discuss screening the menstrual cycle. The other domains include:

1. Physiological biomarkers,
2. Cardiovascular,
3. Psychological,
4. Performance testing,
5. Recovery monitoring,
6. Nutritional assessment,
7. Social, ethical, and environmental considerations.

Part I: Menstrual Cycle Monitoring

The menstrual cycle should be a primary consideration in comprehensive screening protocols. All active females, regardless of their sport, should consider menstrual cycle dysfunction, as it serves as a critical indicator of underlying energy deficiency and hormonal disruption. Despite this, systematic monitoring remains uncommon outside elite environments. Researchers from the United Kingdom examined elite British track and field athletes over five years, and found that 76.8% reported their menstrual cycle negatively impacted performance, with the late luteal and early follicular phases identified as the most detrimental periods⁽⁷⁾.

Menstrual blood loss is a primary cause of iron deficiency and anemia in women of reproductive age. As such, athletes experiencing heavy menstrual bleeding (HMB) are significantly more likely to be diagnosed with anemia and iron deficiency. Approximately 30% of exercising women experience HMB, and symptoms extend beyond performance, with elevated stress levels and reduced mental quality of life observed compared to those with normal menstrual patterns^(8,9). Despite these documented impacts, barriers, including shame and a lack of communication opportunities, prevent effective dialogue between athletes and support staff regarding cycle-related concerns.

Strategies for Implementation and Monitoring

Establishing baseline protocols
Clinicians should consider establishing a baseline menstrual health assessment, in conjunction with daily monitoring of cycle phases and symptomatology, as standard practice. The baseline assessment should include a comprehensive menstrual history (age at menarche, cycle regularity, prior dysfunction), screening for Relative Energy Deficiency in Sport (REDs) using validated questionnaires, and hormonal panel testing when cycles are irregular or amenorrhea is present (see Figure 1). This foundational information can help identify athletes who require immediate medical referral versus those suitable for ongoing monitoring.

Daily tracking: The minimum standard
Daily tracking is the minimum requirement for identifying individual patterns of symptom recurrence (e.g., abdominal cramping or performance fluctuations) and for facilitating informed communication between athletes and coaches. Coaches may instruct athletes to record cycle day, presence/absence of menstruation, symptom severity (using 0-10 scales), and subjective performance ratings. While calendar-based tracking provides a useful starting point, this simple approach enables pattern recognition over two to three cycles without requiring technological investment.

Wearable technology
Wearable tracking technology (WTT) is a practical tool for cycle monitoring that provides physiological data beyond subjective symptom reporting.  Devices such as smart rings utilize skin temperature sensors and heart rate variability to detect physiological shifts associated with the menstrual cycle. For example, the Oura Ring has demonstrated 96.4% accuracy in ovulation detection (within ±3 days) compared to 66.5% for calendar methods, while the Ava bracelet identified the fertile window in 90% of cycles versus 53% for traditional tracking methods⁽¹⁰⁾. This enables athletes to more accurately anticipate cycle phases and adjust training or competition strategies accordingly. These devices typically cost £200-400, making them accessible for semi-elite athletes investing in performance optimization.

Emerging hormonal monitoring technologies
Novel biosensor technologies are advancing beyond passive tracking toward active hormonal monitoring. For example, wearable nanobiosensors (patches) are being developed to monitor estradiol levels noninvasively. These sensors use microscopic sensors to detect estradiol (a key form of estrogen) in sweat, providing a direct correlation to serum estradiol levels to confirm hormonal status⁽¹¹⁾. Such technology could eventually enable athletes to verify ovulation or identify hormonal dysregulation without clinical blood draws. While still in the research phase, these developments signal a future in which athletes can monitor hormonal status as easily as heart rate.

Quantifying heavy menstrual bleeding
Effective HMB screening relies on both qualitative and quantitative assessments to identify risk factors for iron deficiency (ID) and anemia. A specific qualitative protocol used in Australia utilized a four-item clinical screener⁽¹²⁾.

Women are considered to have HMB if they answer "yes" to two or more of the following during their period:

1. Flooding through clothes or bedding,
2. Need for frequent changes of sanitary towels or tampons (every two hours or less, or using >12 items per period),
3. Need for double sanitary protection (using tampons and towels simultaneously),
4. Passing large blood clots.

"The menstrual cycle should be a primary consideration in comprehensive screening protocols."

Quantitatively, HMB is defined as >80 mL per cycle. New "smart menstrual cups" incorporate embedded sensors to address the challenge of measuring blood loss. These devices automatically measure menstrual fluid volume and flow patterns, and are capable of identifying abnormal menstrual flow (with 97% accuracy) and alerting the user to disposal⁽¹³⁾. While commercial pricing remains undisclosed, the technology has attracted significant investment. For instance, UK biotech start-up company Emm recently secured $9 million in seed funding and reports a 30,000-person waitlist ahead of its 2026 launch⁽¹⁴⁾. If commercially accessible to semi-elite and recreational athletes, this could enable earlier detection of iron deficiency and anemia, which is seen in ~50% of HMB-positive athletes⁽⁸⁾.